EN
Endonovo Therapeutics, Inc.
ENDV · OTC
$0.00 +0.00% (+$0.00)
1M +100.00%
Market Cap $31.9K
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0
100.0% downside
Current Price
$0.0001
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ENDV is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
-
N/A PEG N/A
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
13 /100
Poor ROA 5,040.24%
Asset turnover 0.00x
ROIC 4.46%
Debt
0 /100
High Int. coverage -0.83x
Current ratio 0.00x
Net debt/EBITDA N/A
Stability
13 /100
Unstable Rev. volatility 57.86%
EPS volatility 168.11%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ENDV
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Alan Brian Collier
Employees
1
Headquarters
Woodland Hills